Please assess the completion status of the following clinical trial:

Trial Title: A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Crohn's disease.~* Male or female, age \> 18 years.~* Currently treated with a combination therapy with infliximab and anti-metabolites for luminal Crohn's disease.~* Combined therapy with scheduled infliximab and anti-metabolites for at least 8 months.~* Scheduled administration of infliximab 5 mg/Kg every 8 weeks over the last 4 months.~* Antimetabolites administered at a stable dosage for the last 3 months: at least 1 mg/Kg or 2 mg/Kg for mercaptopurine and azathioprine, respectively, or the highest tolerated dosage if intolerance to standard dose; at least 15 mg/week subcutaneously for methotrexate.~* Patients in steroid free clinical remission for at least 6 months according to retrospective assessment of the patients' files.~* CDAI \< 150 at baseline.~* A contraceptive during the whole study for childbearing potential female patients.~* Patients able to understand the information provided to them and to give written informed consent for the study~Exclusion Criteria:~* Patients who have presented a severe acute or delayed reaction to infliximab.~* Perianal fistulae as the main indication for infliximab treatment~* Active perianal/abdominal fistulae at time of inclusion, defined by active drainage~* Patients with ostomy or ileoanal pouch~* Pregnancy or planned pregnancy during the study~* Inability to follow study procedures as judged by the investigator~* Non-compliant subjects.~* Participation in another therapeutic study~* Steroid use ≤6 months prior to screening~* Currently receiving steroids, immunosuppressive agents (other than purine, methotrexate), biologic treatment (other than infliximab) or thalidomide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- INFLIXIMAB AND ANTI METABOLITE (Type: NO_INTERVENTION): continuing scheduled infliximab treatment and anti-metabolite
- STOP INFLIXIMAB CONTINUING ANTI METABOLITE (Type: OTHER): discontinuing infliximab and continuing the anti-metabolite
- CONTINUING INFLIXIMAB AND discontinuing anti-metabolites (Type: OTHER): CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE

Based on this trial design, predict the completion outcome and termination type (if applicable).